Compositions and methods for treating inflammatory pain
The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
1. A method of treating an individual with an inflammatory pain, the method comprising the step of: administering to the individual in need thereof a pharmaceutical composition, wherein administration results in a reduction in a symptom associated with the inflammatory pain, thereby treating the individual, and wherein the pharmaceutical composition comprises:
a) about 10% to about 30% by weight of a non-steroidal anti-pain drug (NSAID):
b) a pharmaceutically-acceptable polyethylene glycol (PEG) polymer in an amount less than about 15% of the total weight of the composition; and
c) a pharmaceutically-acceptable lipid in an amount of at least 50% of the total weight of the composition, the pharmaceutically-acceptable lipid comprising a pharmaceutically-acceptable fat in an amount of at least 30% of the total weight of the composition and a pharmaceutically-acceptable monoglyceride or an acetylated monoglyceride in an amount of at least 20% of the total weight of the composition,
wherein the pharmaceutical composition is formulated to be a solid at a temperature of about 15° C. or lower and have a melting point temperature in the range of about 25° C. or higher.
2. The method according to claim 1 , wherein the inflammatory pain is an acute pain, a subacute pain, or a chronic pain.
3. The method according to claim 1 , wherein the inflammatory pain is a nociceptive pain.
4. The method according to claim 3 , wherein the nociceptive pain is a visceral pain, a deep somatic pain, a superficial somatic pain, or any combination thereof.
5. The method according to claim 1 , wherein the inflammatory pain is a pathological pain.
6. The method according to claim 5 , wherein the pathological pain is a neuropathic pain, a dysfunctional pain, or any combination thereof.
7. The method according to claim 6 , wherein the neuropathic pain is a central neuropathic pain, a peripheral neuropathic pain, a deafferentation pain, or any combination thereof.
8. The method or use according to claim 7 , wherein the peripheral neuropathic pain is a mononeuropathy, a mononeuropathic multiplex, a polyneuropathy, or an autonomic neuropathy.
9. The method or use according to claim 8 , wherein the polyneuropathy is a distal axonopathy, a myelinopathy, or a neuronopathy.
10. The method or use according to claim 7 , wherein the peripheral neuropathic pain is a neuralgia or a complex regional pain syndrome.
11. The method according to claim 1 , wherein the inflammatory pain is a referred pain.
12. The method according to claim 1 , wherein the inflammatory pain is a headache.
13. The method or use according to claim 12 , wherein the headache is a muscular/myogenic headache, a vascular headache, a traction headache, inflammatory headache, a chronic sinusitis headache, a hormone headache, a rebound headache, an organic headache, or an ictal headache.
14. The method according to claim 1 , wherein the severe pain condition is a migraine.
15. The method according to claim 1 , wherein upon administration to an individual, the pharmaceutical composition comprising the therapeutic compound results in a bio-distribution of the therapeutic compound different than a bio-distribution of the therapeutic compound included in the same pharmaceutical composition, except without the pharmaceutically-acceptable adjuvant.
16. The method according to claim 1 , wherein upon administration to an individual, the amount of the therapeutic compound of the pharmaceutical composition delivered to a macrophage is at least 5% of the total amount of the therapeutic compound contained in the administered pharmaceutical composition.
17. The method according to claim 1 , wherein upon administration to an individual, the pharmaceutical composition reduces intestinal irritation by at least 5% when compared to the pharmaceutical composition, except without the pharmaceutically-acceptable adjuvant.
18. The method according to claim 1 , wherein upon administration to an individual, the pharmaceutical composition reduces gastric irritation by at least 5% when compared to the pharmaceutical composition, except without the pharmaceutically-acceptable adjuvant.
19. The method according to claim 1 , wherein the pharmaceutically-acceptable PEG polymer is about 8% (v/v) to 15% of the total weight of the composition.
20. The method according to claim 1 , wherein the pharmaceutically-acceptable monoglyceride is glyceryl monolinoleate.
21. The method according to claim 1 , wherein the pharmaceutically-acceptable fat comprises a triglyceride, an acetylated triglyceride, a triester of glycerol or a fatty acid.
22. The method according to claim 21 , wherein the triglyceride is a mixtures of saturated C 10 -C 18 triglycerides having a melting point around 43° C.
23. The method according to claim 1 , wherein the pharmaceutically-acceptable lipid in an amount of at least 60% of the total weight of the composition.
24. The method according to claim 23 , wherein the pharmaceutically-acceptable fat is in an amount of at least 35% of the total weight of the composition.
25. The method according to claim 1 , wherein the NSAID is a propionic acid derivative NSAID.
26. The method according to claim 25 , wherein the propionic acid derivative NSAID is alminoprofen, benoxaprofen, dexketoprofen, fenoprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, loxoprofen, naproxen, oxaprozin, pranoprofen, or suprofen.